Adial Pharmaceuticals Inc. (NASDAQ:ADIL) and Dermira Inc. (NASDAQ:DERM), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Liquidity

36.6 and 36.6 are the respective Current Ratio and a Quick Ratio of Adial Pharmaceuticals Inc. Its rival Dermira Inc.’s Current and Quick Ratios are 7.1 and 6.9 respectively. Adial Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Dermira Inc.

Insider & Institutional Ownership

Adial Pharmaceuticals Inc. and Dermira Inc. has shares held by institutional investors as follows: 16.8% and 80.11%. Insiders held 3.4% of Adial Pharmaceuticals Inc. shares. Comparatively, 0.6% are Dermira Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Adial Pharmaceuticals Inc. had bearish trend while Dermira Inc. had bullish trend.

Summary

Dermira Inc. beats Adial Pharmaceuticals Inc. on 6 of the 10 factors.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.